Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies

Main Article Content

Andrew Blauvelt
Lawrence Eichenfeld
Michael Kuligowski
May Venturanza
Kang Sun
Jonathan Silverberg


safety, ruxolitinib cream, atopic dermatitis, phase 3 study




1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Eichenfield LF, et al. J Am Acad Dermatol. 2014;71(1):116-132.

3. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

Most read articles by the same author(s)

<< < 4 5 6 7 8 9 10 > >>